Literature DB >> 2144532

Parent reports of disability among 13-year olds with DSM-III disorders.

R McGee1, W Stanton.   

Abstract

This study examined "physical" and "psychological" dimensions of disability associated with different DSM-III disorders in a large sample of 13-year old adolescents. The measure of disability was based upon the World Health Organization (1980) classification. We found that adolescents with multiple DSM-III disorders and those with attention deficit and anxiety disorders showed the highest levels of parent perceived disablement; depression and conduct disorder showed the least. In addition, adolescents with any kind of DSM-III disorder showed a rate of parent-reported hospitalization twice that of the remainder of the sample. They also had poorer perceived health, as suggested by lower parent and self health ratings than those without disorder.

Entities:  

Mesh:

Year:  1990        PMID: 2144532     DOI: 10.1111/j.1469-7610.1990.tb00818.x

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  4 in total

1.  Allergic disorders and attention deficit disorder in children.

Authors:  R McGee; W R Stanton; M R Sears
Journal:  J Abnorm Child Psychol       Date:  1993-02

Review 2.  A critical review of the empirical literature on the relation between anxiety and puberty.

Authors:  Laura E Reardon; Ellen W Leen-Feldner; Chris Hayward
Journal:  Clin Psychol Rev       Date:  2008-09-19

3.  Homotypic versus heterotypic continuity of anxiety symptoms in young adolescents: evidence for distinctions between DSM-IV subtypes.

Authors:  Robert F Ferdinand; Gwen Dieleman; Johan Ormel; Frank C Verhulst
Journal:  J Abnorm Child Psychol       Date:  2007-01-17

4.  A Cross-sectional Study to Assess Disability and Its Correlates among Treatment Seeking Individuals with Alcohol Use Disorders.

Authors:  Yatan Pal Singh Balhara; Shalini Singh; Tamonud Modak; Siddharth Sarkar
Journal:  Indian J Psychol Med       Date:  2017 Jan-Feb
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.